Pfizer announced that Quillivant XR (methylphenidate HCl extended-release) oral suspension is now available for the treatment of attention deficit hyperactivity disorder (ADHD) in patients >6 years old.
The efficacy of Quillivant XR was evaluated in a randomized, double-blind, placebo-controlled, crossover, multicenter, laboratory classroom study of children aged 6–12 years with ADHD (n=45). Quillivant XR significantly improved ADHD symptoms compared to placebo at the primary endpoint of four hours post-dose, and in a secondary analysis, showed significant improvement at every time point measured, from 45 minutes to 12 hours after dosing.
Quillivant, a CII controlled substance, is available in bottles of 300mg, 600mg, 750mg, and 900mg powder for reconstitution containing 25mg/5mL of methylphenidate HCl.
For more information call (866) 706-2400 or visit www.quillivantxr.com